Key result
Severe tricuspid regurgitation was independently associated with mortality, heart failure hospitalization, and cardiovascular death in patients with HFpEF (HR 2.1; 95% CI 1.3-3.3; P<0.01).
Why the study?
Little is known about the prevalence and prognostic value of tricuspid regurgitation in patients with stage B heart failure and stage C HFpEF.
Is moderate/severe tricuspid regurgitation associated with increased mortality and heart failure hospitalization in patients with stage B and C HFpEF?
Cohort (n=2,014)
Is moderate/severe tricuspid regurgitation associated with increased mortality and heart failure hospitalization in patients with stage B and C HFpEF?
Hazard Ratio: 2.1 (95% CI 1.3–3.3)
p-value: p=<0.01
Moderate and severe tricuspid regurgitation are prevalent in stage B and C HFpEF and independently predict mortality and heart failure hospitalization.
May enhance HFpEF risk stratification; leaves open whether TR intervention improves outcomes.
AIMS: Previous studies have demonstrated that moderate/severe tricuspid regurgitation (TR) is associated with adverse outcome in patients with heart failure (HF) with reduced ejection fraction. Little is known about the prevalence and prognostic value of TR in patients of stage B HF and those with stage C HF with preserved ejection fraction (HFpEF). We aimed to investigate the prevalence and prognosis of TR in patients with HFpEF. METHODS AND RESULTS: From 2013 to 2017, 2014 patients with stage B (n = 1341) or C (n = 673) HFpEF were enrolled in the study. Detailed transthoracic echocardiogram was performed, and the severity of TR was graded as no, mild, moderate, and severe. The mean age of the study population was 66.7 ± 14.1 years old, and 46% were men. Mean left ventricular ejection fraction was 62.2 ± 5.5%. The prevalence of moderate/severe TR increased from stage B to C HF (8% to 16%, respectively, P < 0.01). Older age, hyperlipidaemia, atrial fibrillation, left ventricular mass, and right ventricular systolic pressure were independently associated with moderate/severe TR (P < 0.05 for all). With a median follow-up of 3.8 (2.9-4.7) years, 346 patients died and 234 developed HF requiring hospitalization. Kaplan-Meier curve revealed that the presence of moderate/severe TR was associated with all-cause mortality, HF requiring hospitalization and cardiovascular death (log-rank test P < 0.01). Multivariable analysis demonstrated that moderate (hazard ratio = 1.5; 95% confidence interval: 1.1-2.2; P < 0.05) and severe TR (hazard ratio = 2.1; 95% confidence interval: 1.3-3.3; P < 0.01) were independently associated with mortality, HF requiring hospitalization and cardiovascular death. CONCLUSIONS: The presence of moderate/severe TR is not uncommon in patients with stage B HF and stage C HFpEF. Importantly, moderate/severe TR was independently associated with mortality and HF requiring hospitalization.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2020) conducted a cohort in Stage B and C Heart Failure with Preserved Ejection Fraction (n=2,014). Severe tricuspid regurgitation vs. No or mild tricuspid regurgitation was evaluated on Mortality, heart failure requiring hospitalization, and cardiovascular death (HR 2.1, 95% CI 1.3-3.3, p=<0.01). Severe tricuspid regurgitation was independently associated with mortality, heart failure hospitalization, and cardiovascular death in patients with HFpEF (HR 2.1; 95% CI 1.3-3.3; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: